FATE - Fate Ono expand team up on cancer immunotherapy program

Fate Therapeutics (NASDAQ:FATE) said it expanded its cancer immunotherapy collaboration with Japan's Ono Pharmaceutical (OTCPK:OPHLY) (OTC:OPHLF) to include the development of chimeric antigen receptor (CAR) NK cell candidates. In addition, under the expansion, Ono will contribute novel binding domains targeting a second solid tumor antigen, Fate said in a June 28 press release. Under the original 2018 agreement, Ono provided novel binding domains targeting an initial solid tumor antigen, while Fate is currently carrying out preclinical development of an induced pluripotent stem cell (iPSC)-derived CAR T-cell product candidate for solid tumors. Under the amended partnership, Fate will advance iPSC-derived CAR NK and CAR T-cell product candidates to a preclinical milestone, after which Ono has an option to take responsibility for global development and sale, with Fate retaining the right to jointly develop and commercialize in the U.S. and Europe. Fate retains all rights of manufacture of collaboration products on a global

For further details see:

Fate, Ono expand team up on cancer immunotherapy program